Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy

• Status: Unknown status
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to elucidate the influence of anti-hepatitis B virus therapy on safety and survival of HCC patient after transcatheter arterial chemoembolization.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fudan University
• Treatments: Telbivudine

Criteria

Inclusion Criteria:

• hepatocellular carcinoma

• treated with transcatheter arterial chemoembolization (TACE)

• HBVDNA > 10^3copies/mL, including alanine aminotransferase (ALT) normal patient

• expected survive time > 1 year

• HBV marker positive (anyone of HbsAg, HbsAb, HbeAg, HbeAb and HbcAb)

Exclusion Criteria:

• antiviral therapy history

• alanine aminotransferase (ALT) >400 U/L

• serum total bilirubin > 50 μmol/L

• HBVDNA > 10^9copies/mL

• extrahepatic metastasis or main portal vein embolus

• apparent cardiac or pulmonary dysfunction

• liver function: Child B or Child C

• HCV infection